Equillium Inc. (NASDAQ: EQ) Featured in Virtual Coverage of the Summer Investor Summit 2020
Equillium Inc. (NASDAQ: EQ) is a clinical-stage biotechnology company that develops products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Itolizumab has the potential to be a best-in-class disease modifying therapeutic and is advancing itolizumab into clinical development in the following severe immuno-inflammatory disorders:…







